De Motu Cordis Expands Global IP Portfolio
February 18, 2025
Medicine And Healthcare
Leading into J.P. Morgan Healthcare Week, De Motu Cordis (DMC) is pleased to announce the continued growth of our global intellectual property (IP) portfolio, now encompassing 29 granted patents across six patent families.
As a clinical-stage pharmaceutical company based in Brisbane, Australia, DMC is advancing the development of a drug-device dry powder inhaler for the treatment of anaphylaxis and other emergency medicine applications.
Our recently granted patents strengthen protection for the core technologies behind our proprietary device and novel formulation.
Over the past year, we have more than doubled the number of granted patents in key markets, including the United States, Europe, Asia, and Australia.
Looking ahead, we plan to file additional patent applications to safeguard new innovations within our platform technology, reinforcing our commitment to creating transformative solutions in emergency medicine.
About DMC
DMC is a clinical stage medtech company founded in Brisbane, Australia by globally recognised intensive care specialist, researcher, entrepreneur and founder Professor John Fraser AO.
DMC is developing a proprietary inhaled drug delivery platform for use in critical care emergencies. Our lead asset is an investigational inhaled epinephrine product to treat anaphylaxis.
DMC has a strong suite of intellectual property portfolio protecting both its inhaled drug delivery platform and therapeutic formulations. To date, DMC has raised more than AU$30 million from both private and public sector investors.
